Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls
研究概览
简要总结
The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. Furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research.
The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of GLP-1 on food intake and appetite regulation in this group.
详细描述
- Exploration of the physiological role of GLP-1 concerning food intake and appetite regulation in obese adults diagnosed with obesity related genetic disorders.
- Assessment of the effect of GLP-1 on body composition, bone mineral density, energy expenditure, cardiac function, glucose tolerance, insulin sensitivity, lipid concentrations and neuroendocrine function.
- Assessment of the impact of the leptin induced adaptive thermogenesis response in the weight reduced study participants.
- Investigating the alteration of the composition of gut bacteria as well as subjective ratings of satiety and hunger before after supplement with GLP-1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •BMI above 28 (kg/m2)
- •age 18-65 years
- •otherwise healthy
排除标准
- •pregnancy or breastfeeding
- •Type 2 Diabetes
- •suffering from severe medical conditions
- •Recruitment for this study finished November 2015
研究组 & 干预措施
Control Group
4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
干预措施: Liraglutide (Drug)
Case Group
4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
干预措施: Liraglutide (Drug)
结局指标
主要结局
Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls
时间窗: 4 months intervention
pmol/l
次要结局
未报告次要终点
研究者
Eva Pers Winning Iepsen
M.D.
University of Copenhagen